Award of Shares under Share Incentive Plan
Creo Medical Group plc
("Creo" the "Company" or the "Group")
Award of Shares under Share Incentive Plan and Director Dealings
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020, which is available to all of the Company's UK based employees, including Directors.
The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 143,541 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.144 per Ordinary Share on 1 July 2026 to meet its obligations under the SIP (the "Partnership Shares"). Under the terms of the SIP, the Company is required to issue or make available to the SIP, to be allocated to participants, two Ordinary Shares in the Company for each Partnership Share purchased (being 287,082 Ordinary Shares, the "Matching Shares"). As at 1 July 2026, Fiduchi held 875,247 unallocated Ordinary Shares within the SIP. 287,082 of these unallocated Ordinary Shares will be utilised to meet the SIP Matching Share obligation and, accordingly, no new Ordinary Shares are required to be issued to satisfy the Company's obligations under the SIP.
Craig Gulliford and Richard Rees, executive directors of the Company (the "Participating Directors"), have acquired Partnership Shares at a price of £0.144 per share at Fiduchi's sole discretion and received Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following the Transaction, the Participating Directors' shareholdings in the Company are as set out in the table below:
Director
Total number of Ordinary Shares purchased or awarded under SIP
Total number of Ordinary Shares held post Transaction
Craig Gulliford, CEO
18,750
2,062,3851
Richard Rees, CFO
18,750
3,417,0792
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail in relation to the award of the SIP Shares to the Participating Directors.
Notes:
1 Includes shares held by a PCA of Mr Gulliford.
2 Includes shares held by PCAs of Mr Rees.
For further information please contact:
Creo Medical Group plc
Richard Craven, Company Secretary
Via Walbrook PR
Shore Capital (Nominated Adviser and Corporate Broker)
Daniel Bush / Lucy Bowden
+44 (0)20 7408 4090
Walbrook PR Ltd
Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Alice Woodings
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About Creo Medical
Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
For more information, please refer to the website www.creomedical.com
1 Details of person discharging managerial responsibilities / person closely associated
a)
Name
Craig Gulliford
2 Reason for the notification
a)
Position / status
CEO
b)
Initial notification / amendment
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of £0.001 each
GB00BZ1BLL44
b)
Nature of the transaction
Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi
c)
Price(s) and volume(s)
Prices
Volume(s)
£0.144
6,250
d)
Aggregated information
Aggregated volume Price
N/A - Single transaction
e)
Date of the
transaction
2026-07-01
f)
Place of the transaction
London Stock Exchange
1 Details of person discharging managerial responsibilities / person closely associated
a)
Name
Craig Gulliford
2 Reason for the notification
a)
Position / status
CEO
b)
Initial notification / amendment
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of £0.001 each
GB00BZ1BLL44
b)
Nature of the transaction
Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
c)
Price(s) and volume(s)
Prices
Volume(s)
£0.001
12,500
d)
Aggregated information
Aggregated volume Price
N/A - Single transaction
e)
Date of the
transaction
2026-07-01
f)
Place of the transaction
Off-market
1 Details of person discharging managerial responsibilities / person closely associated
a)
Name
Richard Rees
2 Reason for the notification
a)
Position / status
CFO
b)
Initial notification / amendment
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of £0.001 each
GB00BZ1BLL44
b)
Nature of the transaction
Purchase of Ordinary Shares under Share Incentive Plan at the sole discretion of Fiduchi
c)
Price(s) and volume(s)
Prices
Volume(s)
£0.144
6,250
d)
Aggregated information
Aggregated volume Price
N/A - Single transaction
e)
Date of the
transaction
2026-07-01
f)
Place of the transaction
London Stock Exchange
1 Details of person discharging managerial responsibilities / person closely associated
a)
Name
Richard Rees
2 Reason for the notification
a)
Position / status
CFO
b)
Initial notification / amendment
Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Creo Medical Group plc
b)
LEI
213800H188ZDCWWXFA21
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Identification code
Ordinary Shares of £0.001 each
GB00BZ1BLL44
b)
Nature of the transaction
Award of Ordinary Shares (Matching Shares) under Share Incentive Plan
c)
Price(s) and volume(s)
Prices
Volume(s)
£0.001
12,500
d)
Aggregated information
Aggregated volume Price
N/A - Single transaction
e)
Date of the
transaction
2026-07-01
f)
Place of the transaction
Off-market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHUNVURNBUBRAR
